Group 1 - Prothena (PRTA) closed at $9.4, with a 5.5% gain over the past four weeks, and a mean price target of $20.5 suggests an 118.1% upside potential [1] - The mean estimate includes six short-term price targets with a standard deviation of $10.65, indicating variability; the lowest estimate is $8.00 (14.9% decline), while the highest is $36.00 (283% increase) [2] - Analysts show strong agreement on PRTA's ability to report better earnings, with a positive trend in earnings estimate revisions indicating potential upside [4][11] Group 2 - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 73.3%, with three estimates moving higher and no negative revisions [12] - PRTA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - BioLife Solutions, Inc. (BLFS) shares have increased by 11% over the past four weeks, closing at $24.2, with a potential upside indicated by Wall Street analysts' price targets suggesting a mean estimate of $32.67, representing a 35% upside [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $1, where the lowest estimate is $31.00 (28.1% increase) and the highest is $34.00 (40.5% increase) [2] - A smaller standard deviation indicates greater agreement among analysts regarding price targets, which is crucial for understanding the variability of estimates [2][9] Earnings Estimates and Analyst Agreement - Analysts show strong agreement in revising earnings estimates higher for BLFS, which is a positive indicator for potential stock upside [4][11] - Over the past 30 days, one earnings estimate has increased, leading to a 6.9% rise in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - BLFS holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are a common metric, relying solely on them for investment decisions may not be wise due to historical inaccuracies in predicting stock price movements [3][10]

Core Viewpoint - HCI Group (HCI) shares have increased by 11.2% in the past four weeks, closing at $176.42, with a mean price target of $231.67 indicating a potential upside of 31.3% [1] Price Targets - The average price target consists of three estimates ranging from a low of $205.00 to a high of $255.00, with a standard deviation of $25.17, suggesting a potential increase of 16.2% to 44.5% from the current price [2] - A low standard deviation indicates a higher agreement among analysts regarding the price targets, which can be a useful indicator for further research [2][9] Analyst Sentiment - Analysts have shown increasing optimism about HCI's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price increases [4][11] - The Zacks Consensus Estimate for the current year has risen by 5.6% over the past month, with no negative revisions reported [12] Zacks Rank - HCI currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Conclusion on Price Targets - While consensus price targets may not be entirely reliable for predicting stock gains, they can provide a directional guide for price movement [14]

Core Viewpoint - Aecom Technology (ACM) shows potential for significant upside, with a mean price target of $129.08 indicating a 29.7% increase from the current price of $99.56 [1] Price Targets and Estimates - The mean estimate consists of 12 short-term price targets, with a standard deviation of $12.09, indicating variability among analysts [2] - The lowest estimate is $110.00, suggesting a 10.5% increase, while the highest estimate is $150.00, indicating a potential surge of 50.7% [2] - A low standard deviation signifies a high degree of agreement among analysts regarding the stock's price movement [9] Analyst Sentiment and Earnings Estimates - Analysts are optimistic about ACM's earnings prospects, as indicated by a positive trend in earnings estimate revisions [4][11] - The Zacks Consensus Estimate for the current year has increased by 5.8% over the past month, with three estimates revised upward and no negative revisions [12] - ACM holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - While price targets are commonly referenced, they can mislead investors, as empirical research shows they rarely indicate actual stock price movements [7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Dave Inc. (DAVE) has shown a significant price increase of 12.2% over the past four weeks, with analysts projecting a mean price target of $300.11, indicating a potential upside of 56% from the current price of $192.33 [1] Price Targets and Estimates - The mean price target is based on nine short-term estimates with a standard deviation of $31.79, suggesting variability among analysts. The lowest estimate is $250.00, indicating a 30% increase, while the highest estimate is $347.00, suggesting an 80.4% increase [2] - A low standard deviation in price targets indicates a strong agreement among analysts regarding the stock's price movement direction, which can serve as a starting point for further research [9] Analyst Sentiment and Earnings Estimates - Analysts have shown growing optimism regarding DAVE's earnings prospects, as evidenced by a positive trend in earnings estimate revisions. This trend has a strong correlation with near-term stock price movements [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 0.5%, with one estimate moving higher and no negative revisions [12] Zacks Rank and Investment Potential - DAVE currently holds a Zacks Rank 1 (Strong Buy), placing it in the top 5% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does provide a useful guide for the direction of price movement [14]

Core Viewpoint - KalVista Pharmaceuticals, Inc. (KALV) shows significant upside potential with a mean price target of $33.78, indicating an 117.1% increase from its current trading price of $15.56 [1] Price Targets and Analyst Estimates - The mean estimate consists of nine short-term price targets with a standard deviation of $5.4, where the lowest estimate is $22.00 (41.4% increase) and the highest is $39.00 (150.6% increase) [2] - A low standard deviation suggests strong agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about KALV's earnings prospects, as indicated by a positive trend in earnings estimate revisions [11] - Over the last 30 days, the Zacks Consensus Estimate for the current year has increased by 29.2%, with two estimates moving higher and no negative revisions [12] - KALV holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Conclusion on Price Movement - While the consensus price target may not be a reliable indicator of the stock's potential gain, the implied direction of price movement appears to be a useful guide [14]

Group 1 - Nomad Foods (NOMD) closed at $12.92, with a 6.8% gain over the past four weeks, and analysts set a mean price target of $16.83, indicating a 30.3% upside potential [1] - The mean estimate includes six short-term price targets with a standard deviation of $1.47, where the lowest estimate is $15.00 (16.1% increase) and the highest is $18.00 (39.3% increase) [2] - Analysts show strong agreement on the company's ability to report better earnings, with a positive trend in earnings estimate revisions correlating with potential stock upside [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1.5% over the last 30 days, with one estimate moving higher and no negative revisions [12] - NOMD holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be a reliable indicator of potential gains, it does provide a directional guide for price movement [14]

Core Viewpoint - Hinge Health Inc. (HNGE) shows potential for significant upside, with a mean price target of $58.25 indicating a 39% increase from its current price of $41.92 [1] Price Targets and Analyst Estimates - The mean estimate consists of 16 short-term price targets, with a standard deviation of $6.92, indicating variability among analysts [2] - The lowest estimate is $48.00, suggesting a 14.5% increase, while the highest estimate is $72.00, indicating a potential surge of 71.8% [2] - A low standard deviation signifies strong agreement among analysts regarding the stock's price movement [9] Earnings Estimates and Analyst Agreement - Analysts have shown increasing optimism about HNGE's earnings prospects, as evidenced by a strong consensus in revising EPS estimates higher [11] - The Zacks Consensus Estimate for the current year has risen by 63.2% over the past month, with four estimates increasing and no negative revisions [12] - HNGE holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] Caution on Price Targets - Solely relying on price targets for investment decisions may not be prudent, as analysts' ability to set accurate targets has been questioned [3][10] - Price targets can be influenced by business incentives, leading to potentially inflated estimates [8]

Core Viewpoint - LiveOne (LVO) has shown a significant price increase of 21.5% over the past four weeks, with a mean price target of $11.5 indicating a potential upside of 121.2% from its current price of $5.2 [1] Price Targets and Analyst Consensus - The average price target for LVO ranges from a low of $10.00 to a high of $14.00, with a standard deviation of $1.91, suggesting a high degree of agreement among analysts [2] - The lowest estimate indicates a potential increase of 92.3%, while the most optimistic estimate points to a 169.2% upside [2] - A low standard deviation indicates that analysts have a strong consensus on the stock's price movement direction, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Optimism - Analysts have shown growing optimism regarding LVO's earnings prospects, as evidenced by a positive trend in earnings estimate revisions [11] - Over the last 30 days, two earnings estimates have been revised higher, leading to a 10.2% increase in the Zacks Consensus Estimate for the current year [12] - LVO holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating strong potential for upside [13] Caution on Price Targets - While price targets are often sought after by investors, they can be misleading and should not be the sole basis for investment decisions [3][7][10] - Analysts may set overly optimistic price targets due to business incentives, which can inflate expectations [8]

Core Viewpoint - Karyopharm Therapeutics (KPTI) has shown a significant price increase of 58% over the past four weeks, with a mean price target of $14.67 indicating a potential upside of 56.1% from the current price of $9.4 [1] Price Targets and Analyst Estimates - The mean estimate consists of six short-term price targets with a standard deviation of $5.32, where the lowest estimate is $6.00 (indicating a 36.2% decline) and the highest is $21.00 (indicating a 123.4% increase) [2] - A low standard deviation suggests a high degree of agreement among analysts regarding the stock's price movement, which can serve as a starting point for further research [9] Earnings Estimates and Analyst Sentiment - Analysts have shown increasing optimism about KPTI's earnings prospects, with a strong consensus in revising EPS estimates higher, which correlates with potential stock price movements [11] - Over the last 30 days, two estimates have been revised upward, leading to a 13.3% increase in the Zacks Consensus Estimate for the current year [12] Zacks Rank and Investment Potential - KPTI holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimate factors, indicating a strong potential for upside in the near term [13] - While the consensus price target may not be a reliable indicator of the extent of potential gains, it does suggest a positive direction for price movement [14]